Company Name or Ticker Symbol
Search for other Categories
Ctd Holdings Inc  (CTDH)
Other Ticker:  
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
Price: $0.5500 $-0.13 -19.118%
Day's High: $ 0.71 Week Perf: -1.79 %
Day's Low: $ 0.55 30 Day Perf: -5.17 %
Volume (M): 8 52 Wk High: $ 0.77
Volume (M$): $ 4 52 Wk Avg: $ 0.41
Open: 0.71 52 Wk Low: 0.25
You need to upgrade your Flash Player

 Market Capitalization (Millions $) 43
 Shares Outstanding (Millions) 79
 Employees 6
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
Ctd Holdings Inc

We are a biotechnology company that develops cyclodextrin-based products for the treatment of disease. We filed a Type II Drug Master File with the U.S. Food and Drug Administration (“FDA”) in 2014 for our lead drug candidate, Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin) as a treatment for Neimann-Pick Type C disease (“NPC”). NPC is a rare and fatal cholesterol metabolism disease found primarily in children and young adults. In 2015, we launched an International Clinical Program for Trappsol® Cyclo™ as a treatment for NPC. In 2016, we filed an Investigational New Drug application (“IND”) with the FDA, which describes our Phase I clinical plans for a randomized, double blind, parallel group study at a single clinical site in the US. The IND was approved by the FDA in September 2016, and in January 2017 the FDA granted Fast Track designation to Trappsol® Cyclo™ for the treatment of NPC. We have also filed Clinical Trial Applications with several European regulators, including the United Kingdom's Medicines and Healthcare Products Regulatory Agency, which approved our application. We expect to commence a U.S. clinical study in 2017 in which we will provide Trappsol® Cyclo™ intravenously to NPC patients two years of age and older in order to track biochemical markers of cholesterol metabolism and to measure effects on neurologic, lung and liver symptoms, with similar studies to be conducted in Europe.

CTDH is expected to report next financial results on November 09, 2018.
  Company Estimates
  Revenue Outlook
Ctd Holdings Inc does not provide revenue guidance.

Earnings Outlook
Ctd Holdings Inc does not provide earnings estimates.

Geographic Revenue Dispersion

Neophotonics Corp

Despite Strong Sales Profitability not Reached

Although company's Sales increased by 10.77 % from the same quarter a year ago to $81.10 millions in the second quarter, Neophotonics Corp losses widen at $-0.24 loss per share.

CTDH's Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 71.37
Price to Sales (Expected) -
Price to Book 43.22
CTDH's Financial Strength Current
Quick Ratio 1.2
Working Capital Ratio 1.65
Leverage Ratio (MRQ) 1.28
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -
Per Share Current
Earnings (TTM) -0.06 $
Revenues (TTM) 0.01 $
Cash Flow (TTM) 0 $
Cash 0.02 $
Book Value 0.01 $
Dividend (TTM) 0 $

• View Valuation Comparisons • View Growth Rates Comparisons

You need to upgrade your Flash Player
CTDH's Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -686,665
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) 0.28
Asset Turnover Ratio (TTM) -
CTDH's Profitability Ratio Current
Gross Margin -
Operating Margin -
Net Margin -
Net Cash Flow Margin -
Effective Tax Rate (TTM) -
Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Payout Ratio (TTM) -
• View Efficiency Comparisons • View Profitability Comparisons • View Management Effectiveness

You need to upgrade your Flash Player

You need to upgrade your Flash Player
Major Competitors Stock performance

5 Days Decrease / Increase
• View Complete Report


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

ISYG's Profile

Stock Price

ISYG's Financials

Business Description


Charts & Quotes

ISYG's News


ISYG's Competitors

Customers & Markets

Economic Indicators

ISYG's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength



Management Effectivness


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries





At a Glance








About us

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2018 CSIMarket, Inc. All rights reserved. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)
Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071